High-content analysis in toxicology: Screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translational safety biomarkers

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 1, 2014, Pages 4-17

  O'Brien, Peter J ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b Advanced Diagnostics Laboratory Park West Enterprise Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; AMIODARONE; AZATHIOPRINE; BIOLOGICAL MARKER; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CERIVASTATIN; CITICOLINE; DIDANOSINE; DIQUAT; DOXORUBICIN; DRUG; ERYTHROMYCIN; FENOFIBRATE; FLUCYTOSINE; FLUINDOSTATIN; FOSCARNET; FUROSEMIDE; IMIPRAMINE; INDOMETACIN; ISOXICAM; MENADIONE; MEVINOLIN; PARACETAMOL; PENTACHLOROPHENOL; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; UNINDEXED DRUG; XENOBIOTIC AGENT; XIMELAGATRAN;

ARTICLE; CONTENT ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; DRUG SAFETY; HORMESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TOTAL QUALITY MANAGEMENT; TOXICITY TESTING; TOXICOLOGY; TRANSLATIONAL RESEARCH; ANIMAL; ANIMAL MODEL; CELL LINE; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; LIVER CELL; METABOLISM; PROCEDURES;

ANIMALIA;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATOCYTES; HORMESIS; HUMANS; MODELS, ANIMAL; TOXICITY TESTS;

EID: 84902106571     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12227     Document Type: Article

References (50)

1. Segall MD, Barber C. Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discovery Today 2014, DOI: 10.1016/j.drudis.2014.01.006.
2. Fung M, Thornton A, Mybeck K, Hsiao-Hui W, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960-1999. Drug Inf J 2001;35:293-317.
3. Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today 2007;12:777-85.
4. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
5. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67.
6. O'Brien P, Haskins JR. In vitro cytotoxicity assessment. Methods Mol Biol 2007;356:415-25.
7. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 2006;80:580-604.
8. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225.
9. Pohjala L, Tammela P, Samanta SK, Yli-Kauhaluoma J, Vuorela P. Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assays. Anal Biochem 2007;362:221-8.
10. Westerink WMA, Schoonen WGEJ. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007;21:1581-91.
11. Slaughter MR, Thakkar H, O'Brien PJ. Effect of diquat on the antioxidant system and cell growth in human neuroblastoma cells. Toxicol Appl Pharmacol 2002;178:63-70.
12. Xu JJ, Diaz D, O'Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 2004;150:115-28.
13. O'Brien PJ. Chapter 14. Discovery toxicology screening: predictive, in vitro cytotoxicity. In: Faller B, Urban L (eds). Hit and Lead Profiling: Identification and Optimization of Drug-Like Molecules. John Wiley & Sons, New Jersey, NJ, 2009;325-34.
14. O'Brien PJ. Chapter 13: High content analysis of sublethal cytotoxicity in human HepG2 hepatocytes for assessing potential and mechanism for chemical and drug-induced human toxicity. In: Haney SA (ed.). High Content Screening: Science, Techniques and Applications. John Wiley & Sons, Hoboken, NJ, 2008;293-316.
15. Lieggi NT, Edvardsson A, O'Brien PJ. Translation of cytotoxicity biomarkers detected with high content analysis from an in vitro predictive model to an in vivo cell model. Toxicol In Vitro 2010;24:2063-71.
16. Haskins JR, Rowse P, Rahbari R, de La Iglesia FA. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 2001;75:425-38.
17. Giuliano KA, Haskins JR, Taylor DL. Advances in high content screening for drug discovery. Assay Drug Dev Technol 2003;1:1565-77.
18. Abraham VC, Taylor L, Haskins JR. High content screening applied to large-scale cell biology. Trends Biotechnol 2004;22:15-72.
19. Schoonen WGEJ, Westerink WMA, de Roosa JADM, Débiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. I Mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol In Vitro 2005a;19:491-503.
20. Schoonen WGEJ, de Roosa JADM, Westerink WMA, Débiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II Mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 2005b;19:491-503.
21. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008;105:97-105.
22. Abraham VC. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screen 2008;13:527-37.
23. Perlman AE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ. Multidimensional drug profiling by automated microscopy. Science 2004;306:1194-8.
24. Walsh EG, Maher S, Devocelle M, O'Brien PJ, Baird AW, Brayden DJ. High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. Peptides 2011;32:1764-73.
25. Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O'Connor JE et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci 2012;127:187-98.
26. Persson M, Løye AF, Mow T, Hornberg JJ. A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 2013;68:302-13.
27. Garside H, Marcoe KF, Chesnut-Speelman J, Foster AJ, Muthas D, Kenna JG et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol In Vitro 2014;28:171-81.
28. Diaz D, O'Brien PJ. Defining the sequence of events in cerivastatin toxicity using a high content multi-parametric cytotoxicity assay. Eur Pharmaceut Rev 2006;11:38-45.
29. Ainscow EK, Pilling JE, Brown NM, Orme AT, Sullivan M, Hargreaves AC et al. Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures. Expert Opin Drug Saf 2008;7:351-65.
30. Jan E, Byrne SJ, Cuddihy M, Davies AM, Volkov Y, Gun'ko YK et al. High-content screening as a universal tool for fingerprinting of cytotoxicity of nanoparticles. ACS Nano 2008;2:928-38.
31. George S, Pokhrel S, Xia T, Gilbert B, Ji Z, Schowalter M et al. Use of a rapid cytotoxicity screening approach to engineer a safer zinc oxide nanoparticle through iron doping. ACS Nano 2010;26:15-29.
32. Ramery E, O'Brien PJ. Evaluation of the cytotoxicity of organic dust components on THP1 monocytes-derived macrophages using high content analysis. Environ Toxicol 2014;29:310-19.
33. Morelli JK, Buehrle M, Pognan R, Barone LR, Fieles W, Ciaccio PJ. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol Toxicol 2006;22:15-27.
34. Wu Y, Connors D, Barber L, Jayachandra S, Hanumegowda UM, Adams SP. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. Toxicol In Vitro 2009;23:1170-8.
35. Radio NM, Breier JM, Shafer TJ, Mundy WR. Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. Toxicol Sci 2008;105:106-18.
36. Mundy WR, Radio NM, Freudenrich TM. Neuronal models for evaluation of proliferation in vitro using high content screening. Toxicology 2010;270:121-30.
37. Diaz D, Scott A, Carmichael P, Shi W, Costales C. Evaluation of an automated in vitro micronucleus assay in CHOK1 cells. Mutat Res 2007;630:1-13.
38. Scott A, Malcomber S, Maskell S, Moore C, Windebank S, Diaz D et al. An assessment of the performance of an automated scoring system (Cellomics) for the in vitro micronucleus assay in CHO-K1 cells. Toxicology 2007;231:111-2.
39. Hippisley-Cox J. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
40. Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006;5:651-6.
41. Borzelleca JF. Paracelsus: herald of modern toxicology. Toxicol Sci 2000;53:2-4.
42. Davila JC, Xu JJ, Hoffmaster KA, O'Brien PJ, Storm SC. Chapter 1. Current in vitro models to study drug-induced liver injury. In: Sahu S (ed.). Hepatotoxicity: From Genomics to In Vitro and In Vivo Models. John Wiley & Sons Ltd, Chichester, UK, 2008;3-55.
43. Rawlinson LA, O'Brien PJ, Brayden DJ. High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. J Control Release 2010;146:84-92.
44. O'Brien PJ, Domingos MC. Use of high content analysis in toxicologic clinical pathology for identification and monitoring of translational safety biomarkers. Drug Discov 2010;5:50-5.
45. Pospischil A, Walther P, Dingemanse J. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells. Exp Toxicol Pathol 2010;62:567-71.
46. Lin CH, Sloan DD, Dang CH, Wagner T, Cabrera AJ, Tobin NH et al. Assessment of mitochondrial toxicity by analysis of mitochondrial protein expression in mononuclear cells. Cytometry B Clin Cytom 2009;76:181-90.
47. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Methods Mol Biol 2008;410:185-216.
48. Luna AL, Acosta-Saavedra LC, Lopez-Carrillo L, Conde P, Vera E, De Vizcaya-Ruiz A et al. Arsenic alters monocyte superoxide anion and nitric oxide production in environmentally exposed children. Toxicol Appl Pharmacol 2010;245:244-51.
49. Berger I, Segal I, Shmueli D, Saada A. The effect of antiepileptic drugs on mitochondrial activity: a pilot study. J Child Neurol 2010;25:541-5.
50. Pointon A, Abi-Gerges N, Cross NH, Sidaway JE. Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol Sci 2013;132:317-26.